Marks Group Wealth Management, Inc
Source: SEC Form 13F · as of Mar 2026Marks Group Wealth Management, Inc holds 24 biotech & pharma companies tracked by BioSniper, totaling $45.6M in value as of Mar 2026 (SEC Form 13F).
Companies held
24
Total value held
$45.6M
| Company | Shares | Value |
|---|---|---|
| UNHUnitedHealth Group Incorporated Common Stock (DE) | 39,870 | $10.8M |
| ICLRICON plc | 50,201 | $5.6M |
| IQVIQVIA Holdings Inc. | 32,107 | $5.5M |
| AZNASTRAZENECA PLC | 18,442 | $3.6M |
| IDXXIDEXX LABORATORIES INC /DE | 5,286 | $3.0M |
| GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares) | 53,330 | $2.9M |
| AMGNAMGEN INC | 6,508 | $2.3M |
| LLYELI LILLY & Co | 2,123 | $2.0M |
| CORCencora Inc. | 6,208 | $2.0M |
| ABTABBOTT LABORATORIES | 11,795 | $1.2M |
| CYTKCYTOKINETICS INC | 16,835 | $1.1M |
| JNJJOHNSON & JOHNSON | 3,632 | $888K |
| APGEApogee Therapeutics, Inc. | 8,243 | $694K |
| PMPhilip Morris International Inc | 3,556 | $588K |
| ALNYALNYLAM PHARMACEUTICALS, INC. | 1,650 | $546K |
| ERASErasca, Inc. | 29,879 | $483K |
| PCVXVaxcyte, Inc. | 6,558 | $381K |
| ACLXArcellx, Inc. | 3,180 | $365K |
| KYMRKymera Therapeutics, Inc. | 4,003 | $333K |
| ABBVAbbVie Inc. | 1,501 | $326K |
| BNTXBioNTech SE | 3,454 | $307K |
| MRKMerck & Co., Inc. | 2,546 | $306K |
| GILDGILEAD SCIENCES, INC. | 2,000 | $279K |
| NVSNovartis AG | 1,618 | $247K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.